Pacira BioSciences, Inc. (PCRX)
USD 24.38
(2.91%)
USD 24.38
(2.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 326.37 Million USD | -12.83% |
| 2022 | 396.6 Million USD | 47.74% |
| 2021 | 268.44 Million USD | 2.93% |
| 2020 | 260.8 Million USD | -6.39% |
| 2019 | 278.6 Million USD | 19.6% |
| 2018 | 232.95 Million USD | 6.48% |
| 2017 | 218.78 Million USD | 10.33% |
| 2016 | 198.29 Million USD | 18.24% |
| 2015 | 167.7 Million USD | 33.74% |
| 2014 | 125.39 Million USD | 49.16% |
| 2013 | 84.06 Million USD | 49.47% |
| 2012 | 56.24 Million USD | 60.55% |
| 2011 | 35.03 Million USD | 42.07% |
| 2010 | 24.65 Million USD | -21.1% |
| 2009 | 31.25 Million USD | -25.28% |
| 2008 | 41.82 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 88.46 Million USD | -1.99% |
| 2024 Q1 | 90.26 Million USD | 5.86% |
| 2023 Q3 | 103.09 Million USD | 5.21% |
| 2023 Q4 | 85.26 Million USD | -17.3% |
| 2023 FY | 345.69 Million USD | -12.83% |
| 2023 Q2 | 97.99 Million USD | -4.21% |
| 2023 Q1 | 102.3 Million USD | 6.79% |
| 2022 Q4 | 95.79 Million USD | 0.83% |
| 2022 Q2 | 105.6 Million USD | 5.41% |
| 2022 Q1 | 100.18 Million USD | 33.01% |
| 2022 FY | 396.6 Million USD | 47.74% |
| 2022 Q3 | 95.01 Million USD | -10.03% |
| 2021 Q2 | 65.35 Million USD | -1.53% |
| 2021 Q1 | 66.36 Million USD | -5.36% |
| 2021 Q4 | 75.32 Million USD | 20.8% |
| 2021 Q3 | 62.35 Million USD | -4.59% |
| 2021 FY | 268.44 Million USD | 2.93% |
| 2020 Q1 | 62.56 Million USD | -17.51% |
| 2020 FY | 260.8 Million USD | -6.39% |
| 2020 Q2 | 58.92 Million USD | -5.81% |
| 2020 Q3 | 69.17 Million USD | 17.39% |
| 2020 Q4 | 70.12 Million USD | 1.37% |
| 2019 Q4 | 75.84 Million USD | 4.83% |
| 2019 Q2 | 68.72 Million USD | 9.25% |
| 2019 Q3 | 72.35 Million USD | 5.28% |
| 2019 FY | 278.6 Million USD | 19.6% |
| 2019 Q1 | 62.9 Million USD | 6.94% |
| 2018 Q3 | 59.07 Million USD | 4.58% |
| 2018 Q1 | 58.56 Million USD | 19.03% |
| 2018 FY | 232.95 Million USD | 6.48% |
| 2018 Q4 | 58.82 Million USD | -0.43% |
| 2018 Q2 | 56.48 Million USD | -3.55% |
| 2017 FY | 218.78 Million USD | 10.33% |
| 2017 Q4 | 49.2 Million USD | -6.13% |
| 2017 Q3 | 52.41 Million USD | -10.25% |
| 2017 Q2 | 58.4 Million USD | -0.59% |
| 2017 Q1 | 58.75 Million USD | 13.55% |
| 2016 Q4 | 51.74 Million USD | 12.32% |
| 2016 Q2 | 53.03 Million USD | 11.76% |
| 2016 Q1 | 47.45 Million USD | -6.42% |
| 2016 FY | 198.29 Million USD | 18.24% |
| 2016 Q3 | 46.06 Million USD | -13.13% |
| 2015 Q1 | 37.39 Million USD | 7.13% |
| 2015 Q4 | 50.7 Million USD | 23.06% |
| 2015 FY | 167.7 Million USD | 33.74% |
| 2015 Q3 | 41.2 Million USD | 7.3% |
| 2015 Q2 | 38.4 Million USD | 2.69% |
| 2014 Q4 | 34.9 Million USD | 6.93% |
| 2014 FY | 125.39 Million USD | 49.16% |
| 2014 Q3 | 32.64 Million USD | 8.61% |
| 2014 Q2 | 30.05 Million USD | 8.13% |
| 2014 Q1 | 27.79 Million USD | 11.14% |
| 2013 Q4 | 25 Million USD | 17.51% |
| 2013 Q1 | 18.84 Million USD | 13.45% |
| 2013 FY | 84.06 Million USD | 49.47% |
| 2013 Q2 | 18.93 Million USD | 0.51% |
| 2013 Q3 | 21.28 Million USD | 12.38% |
| 2012 Q2 | 12.28 Million USD | -1.29% |
| 2012 Q1 | 12.44 Million USD | 33.4% |
| 2012 Q3 | 14.9 Million USD | 21.33% |
| 2012 Q4 | 16.6 Million USD | 11.42% |
| 2012 FY | 56.24 Million USD | 60.55% |
| 2011 FY | 35.03 Million USD | 42.07% |
| 2011 Q1 | 7.31 Million USD | 26.98% |
| 2011 Q2 | 9.05 Million USD | 23.69% |
| 2011 Q3 | 9.33 Million USD | 3.09% |
| 2011 Q4 | 9.33 Million USD | -0.02% |
| 2010 Q4 | 5.76 Million USD | -22.23% |
| 2010 Q3 | 7.41 Million USD | 27.01% |
| 2010 Q2 | 5.83 Million USD | 3.2% |
| 2010 Q1 | 5.65 Million USD | -34.39% |
| 2010 FY | 24.65 Million USD | -21.1% |
| 2009 Q3 | 7.16 Million USD | 0.0% |
| 2009 Q4 | 8.61 Million USD | 20.32% |
| 2009 FY | 31.25 Million USD | -25.28% |
| 2008 FY | 41.82 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -3854.708% |
| Alpha Teknova, Inc. | 45.85 Million USD | -611.697% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -66.533% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -627.643% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -105.0% |
| Cosmos Health Inc. | 26.18 Million USD | -1146.628% |
| Journey Medical Corporation | 54.59 Million USD | -497.826% |
| Embecta Corp. | 528.4 Million USD | 38.233% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -20.037% |
| Dynavax Technologies Corporation | 219.14 Million USD | -48.932% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 44.682% |
| PainReform Ltd. | 9.58 Million USD | -3305.436% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2386.782% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2386.782% |
| SCYNEXIS, Inc. | 51.84 Million USD | -529.488% |
| Safety Shot Inc | 12.1 Million USD | -2595.171% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -10533.985% |
| Procaps Group, S.A. | 199.47 Million USD | -63.616% |
| Theratechnologies Inc. | 72.75 Million USD | -348.591% |
| Harrow Health, Inc. | 89.97 Million USD | -262.75% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -3355.187% |
| Biofrontera Inc. | 39.95 Million USD | -716.78% |
| DURECT Corporation | 43.71 Million USD | -646.602% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 38.304% |
| Cronos Group Inc. | 96.7 Million USD | -237.484% |
| OptiNose, Inc. | 85.1 Million USD | -283.513% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -40.605% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -733.594% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 3513.628% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -3.897% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -3254.05% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -658.301% |
| Radius Health, Inc. | 265.92 Million USD | -22.731% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -2257.89% |
| ProPhase Labs, Inc. | 37.85 Million USD | -762.245% |
| Phibro Animal Health Corporation | 260.29 Million USD | -25.386% |
| Procaps Group S.A. | 187.24 Million USD | -74.305% |
| Alvotech | 285.43 Million USD | -14.343% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -3221.903% |
| Viatris Inc. | 5.96 Billion USD | 94.529% |
| Rockwell Medical, Inc. | 15.37 Million USD | -2022.915% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -445.416% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1380.636% |
| Tilray Brands, Inc. | 251.35 Million USD | -29.846% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -565.559% |
| Shineco, Inc. | 17.94 Million USD | -1718.455% |
| PetIQ, Inc. | 192.72 Million USD | -69.349% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -8077.542% |
| Incannex Healthcare Limited | 30.05 Million USD | -986.005% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 79.557% |
| Alimera Sciences, Inc. | 62.64 Million USD | -421.028% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -42703.99% |
| Assertio Holdings, Inc. | 368.58 Million USD | 11.451% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -5445.375% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1732.7% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1441.769% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1451.067% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -97.845% |
| Hempacco Co., Inc. | 7.59 Million USD | -4196.442% |
| Talphera, Inc. | 11.99 Million USD | -2621.169% |
| Alvotech | 285.43 Million USD | -14.343% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -131.944% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 5.371% |
| Currenc Group, Inc. | 24 Million USD | -1259.786% |
| Kamada Ltd. | 45.42 Million USD | -618.481% |
| Indivior PLC | 911 Million USD | 64.174% |
| Evoke Pharma, Inc. | 12.4 Million USD | -2530.028% |
| Flora Growth Corp. | 10.57 Million USD | -2985.14% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1451.067% |
| Evolus, Inc. | 189.75 Million USD | -71.996% |
| HUTCHMED (China) Limited | 436.23 Million USD | 25.183% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -111.749% |
| Akanda Corp. | 3.48 Million USD | -9269.205% |